ascopubs.org

First-in-human trial of SYS6010 combined with SYH2051 in patients with advanced gastrointestinal tumors.

Results from a phase 1/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer. Precemtabart tocentecan (M9140), an ...
ascopubs.org

Phase II trial of SYS6010, an EGFR antibody-drug conjugate (ADC) in patients with advanced esophageal squamous cell carcinoma (ESCC).

Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: ...
AASTOCKS.com

CSPC PHARMA (01093.HK) Initiates Phase III Clinical Study in China for SYS6010 Combined with Enlangsubai Monoclonal Antibody for NSCLC Treatment

CSPC PHARMA (01093.HK) announced that the Phase III clinical study in China of SYS6010 developed by the Group in combination ...
The Globe and Mail

CSPC’s ADC SYS6010 Wins New Breakthrough Status in China Esophageal Cancer

CSPC Pharmaceutical Group ( (HK:1093)) has provided an update. CSPC Pharmaceutical Group said its independently developed drug SYS6010, a humanised EGFR-targeting antibody-drug conjugate, has received ...
Nasdaq

CSPC Pharmaceutical Gains Breakthrough Status for Cancer Therapy

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
阿思達克財經網

CSPC PHARMA Initiates Phase III Clinical Study in China for SYS6010 Combined with Enlangsubai Monoclonal Antibody for NSCLC Treatment

STOCK INFO CSPC PHARMA (01093.HK) -0.210 (-2.552%)Short selling $448.73M; Ratio 31.428% announced that the Phase III clinical study in China of SYS6010 developed by the Group in combination with ...